EGFR and non-small cell lung carcinoma: EGFR-TKI therapy is the standard treatment for patients with advanced EGFR-mutated NSCLC; it has a higher response rate and provides better symptom control and quality of life improvements compared to conventional chemotherapy or immunotherapy.(15, 16) However, disease progression with acquired resistance is inevitable and tissue re-biopsy or liquid biopsy is recommended for the guide of second-line treatment.